MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.23886

Медицинская библиотека · American journal of hematology · 2014

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.

Kadia Tapan M, Kantarjian Hagop M, Thomas Deborah A, O'Brien Susan, Estrov Zeev, Ravandi Farhad, Jabbour Elias, Pemmaraju Naveen, Daver Naval, Wang Xuemei, Jain Preetesh, Pierce Sherry, Brandt Mark, Garcia-Manero Guillermo, Cortes Jorge, Borthakur Gautam

Клиническое исследование II фазыСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Newer approaches are needed for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). Asparaginase-based regimens are active in the treatment of pediatric ALL and may be important in salvage therapy for adult patients. We conducted a pilot trial combining methotrexate, vincristine, PEGylated-asparaginase, and dexamethasone (MOpAD) in adults with relapsed or refractory ALL. We added tyrosine kinase inhibitors in patients with Philadelphia chromosome positive (Ph+) ALL and rituximab in patients with CD20 positive B-cell ALL. Among 37 patients treated (median age 42 years; median 2 prior therapies), the complete remission (CR) rate was 28% and an overall response rate (ORR) was 39%. The median CR duration was 4.3 months. Patients with Ph+ ALL had CR and ORR of 50% and 67%, respectively and the CR and ORR in patients with T-cell leukemia were 45% and 56%, respectively. The median survival in patients with CR/CRp was 10.4 versus 3.4 months in nonresponders (P = 0.02). The most common grade 3 or 4 nonhematologic toxicities were elevations in bilirubin and transaminases, nausea, peripheral neuropathy, and hyperglycemia, which were managed with supportive care, dose adjustments, and interruptions.

Для цитирования: Kadia Tapan M, Kantarjian Hagop M, Thomas Deborah A, O'Brien Susan, Estrov Zeev, Ravandi Farhad, Jabbour Elias, Pemmaraju Naveen, Daver Naval, Wang Xuemei, Jain Preetesh, Pierce Sherry, Brandt Mark, Garcia-Manero Guillermo, Cortes Jorge, Borthakur Gautam. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.. American journal of hematology. 2014. DOI: 10.1002/ajh.23886.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.